TY - JOUR
T1 - Effects of growth hormone treatment in adults with Prader-Willi syndrome
AU - Butler, M. G.
AU - Smith, B. K.
AU - Lee, J.
AU - Gibson, C.
AU - Schmoll, C.
AU - Moore, W. V.
AU - Donnelly, J. E.
N1 - Funding Information:
We thank the adults with Prader–Willi syndrome and their families who participated in the study. The study was partially supported by Genentech, Inc. who also provided the growth hormone and supplies. We thank Carla Meister for the expert preparation of the manuscript.
PY - 2013/6
Y1 - 2013/6
N2 - Objective: Since limited data exist on adults with Prader-Willi syndrome (PWS) and growth hormone (GH) treatment, we report our experience on the effects of treatment for one year on body composition, physical activity, strength and energy expenditure, diet, general chemistry and endocrine data with quality of life measures. Design: We studied 11 adults with PWS (6F:5M; average age = 32 yrs) over a 2 year period with GH treatment during the first year only. Electrolytes, IGF-I, glucose, thyroid, insulin, lipids, body composition, physical activity and strength, diet, energy expenditure and quality of life data were collected and analyzed statistically using linear modeling at baseline, at 12 months following GH therapy and at 24 months after treatment cessation for 12 months. Results: Total lean muscle mass was significantly increased (p < 0.05) during GH treatment along with moderate-vigorous physical activity and plasma IGF-I and HDL levels, but returned to near baseline after treatment. Percent body fat decreased during the 12. months of GH treatment but increased after treatment. Conclusions: Previously reported beneficial effects of GH treatment in children with PWS were found in our adults regarding body composition, physical activity and plasma HDL and IGF-I levels. Several beneficial effects diminished to near baseline after cessation of GH treatment for 12. months supporting the continuation of treatment in PWS into adulthood and possibly adults not previously treated during childhood.
AB - Objective: Since limited data exist on adults with Prader-Willi syndrome (PWS) and growth hormone (GH) treatment, we report our experience on the effects of treatment for one year on body composition, physical activity, strength and energy expenditure, diet, general chemistry and endocrine data with quality of life measures. Design: We studied 11 adults with PWS (6F:5M; average age = 32 yrs) over a 2 year period with GH treatment during the first year only. Electrolytes, IGF-I, glucose, thyroid, insulin, lipids, body composition, physical activity and strength, diet, energy expenditure and quality of life data were collected and analyzed statistically using linear modeling at baseline, at 12 months following GH therapy and at 24 months after treatment cessation for 12 months. Results: Total lean muscle mass was significantly increased (p < 0.05) during GH treatment along with moderate-vigorous physical activity and plasma IGF-I and HDL levels, but returned to near baseline after treatment. Percent body fat decreased during the 12. months of GH treatment but increased after treatment. Conclusions: Previously reported beneficial effects of GH treatment in children with PWS were found in our adults regarding body composition, physical activity and plasma HDL and IGF-I levels. Several beneficial effects diminished to near baseline after cessation of GH treatment for 12. months supporting the continuation of treatment in PWS into adulthood and possibly adults not previously treated during childhood.
KW - Body composition
KW - Energy expenditure
KW - Growth hormone treatment
KW - Physical activity
KW - Prader-Will syndrome adults
UR - http://www.scopus.com/inward/record.url?scp=84876706642&partnerID=8YFLogxK
U2 - 10.1016/j.ghir.2013.01.001
DO - 10.1016/j.ghir.2013.01.001
M3 - Article
C2 - 23433655
AN - SCOPUS:84876706642
SN - 1096-6374
VL - 23
SP - 81
EP - 87
JO - Growth Hormone and IGF Research
JF - Growth Hormone and IGF Research
IS - 3
ER -